ATQP Stock Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ATQP from our risk checks.
Vericel Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.20 |
| 52 Week High | US$48.80 |
| 52 Week Low | US$27.40 |
| Beta | 1.73 |
| 1 Month Change | 0% |
| 3 Month Change | 15.51% |
| 1 Year Change | 57.66% |
| 3 Year Change | -17.71% |
| 5 Year Change | 162.45% |
| Change since IPO | 72.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATQP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -1.2% | 1.7% |
| 1Y | 57.7% | -23.0% | 2.3% |
Return vs Industry: ATQP exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: ATQP exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| ATQP volatility | |
|---|---|
| ATQP Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ATQP has not had significant price volatility in the past 3 months.
Volatility Over Time: ATQP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 314 | Nick Colangelo | vcel.com |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation Fundamentals Summary
| ATQP fundamental statistics | |
|---|---|
| Market cap | €2.09b |
| Earnings (TTM) | -€2.97m |
| Revenue (TTM) | €184.56m |
11.3x
P/S Ratio-699.8x
P/E RatioIs ATQP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATQP income statement (TTM) | |
|---|---|
| Revenue | US$197.52m |
| Cost of Revenue | US$61.94m |
| Gross Profit | US$135.58m |
| Other Expenses | US$138.76m |
| Earnings | -US$3.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.066 |
| Gross Margin | 68.64% |
| Net Profit Margin | -1.61% |
| Debt/Equity Ratio | 0% |
How did ATQP perform over the long term?
See historical performance and comparison